Abstract Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid
system modulator for the adjunctive treatment of patients with major depressive disorder …

Background The endogenous opioid system is a fundamental regulator of mood in humans.
Previously reported clinical trials have demonstrated the efficacy of the investigational agent …

The endogenous opioid system is thought to play an important role in the regulation of
mood. Buprenorphine/samidorphan (BUP/SAM) combination is an investigational opioid …

Objective: Major depressive disorder has been associated with dysregulation of the
endogenous opioid system. The authors sought to determine whether opioid modulation …

Introduction: Treatment resistant depression (TRD) represents approximately 20% of all
individuals receiving care for major depressive disorder. The opioidergic system is identified …

Background Depressive disorders are common. Many patients with major depression do not
achieve remission with available treatments. Buprenorphine has been raised as a potential …

Introduction: Past trials of buprenorphine (BUP) in the treatment of major depressive
disorder (MDD) have displayed favorable results, although its clinical utility was limited by …

Although opioids have known antidepressant activity, their use in major depressive disorder
(MDD) has been greatly limited by risk of abuse and addiction. Our aim was to determine …

Buprenorphine/samidorphan combination (BUP/SAM) is an opioid system modulator being
investigated as adjunctive treatment for major depressive disorder. BUP/SAM is a fixed …

Rates of major depressive disorder (MDD) are disproportionally high in subjects with opioid
use disorder (OUD) relative to the general population. MDD is often more severe in OUD …